Wide Ranks

ALT

Altimmune, Inc.

8.73

Top Statistics
Market Cap 620 M Forward PE -7.81 Revenue Growth -98.60 %
Current Ratio 16.87 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -4.87 Enterprise / Revenue 9294.44 Price To Sales Trailing12 Months 11940.73
Profitability
Profit Margins 0.00 % Operating Margins -495340.00 %
Balance Sheet
Total Cash 139 M Total Cash Per Share 1.96 Total Debt 1 M
Total Debt To Equity 1.33 Current Ratio 16.87 Book Value Per Share 1.88
All Measures
Short Ratio 662.00 % Message Board Id finmb_4866807 Shares Short Prior Month 22 M
Return On Equity -0.7296 City Gaithersburg Uuid dfbfc9cc-7a23-3560-b04c-b1a5faf1ec3e
Previous Close 8.43 First Trade Date Epoch Utc 1 B Book Value 1.88
Beta 0.0720 Total Debt 1 M Volume 2 M
Price To Book 4.66 Last Split Date 1 B Fifty Two Week Low 3.16
Total Cash Per Share 1.96 Total Revenue 52000 Shares Short Previous Month Date 1 B
Target Median Price 24.50 Max Age 86400 Recommendation Mean 1.78
Sand P52 Week Change 0.3133 Operating Margins -495340.00 % Target Mean Price 21.25
Net Income To Common -103520000 Short Percent Of Float 0.3219 Implied Shares Outstanding 71 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 3 M
Average Volume10days 3 M Total Cash 139 M Next Fiscal Year End 1 B
Revenue Per Share 0.0010 Held Percent Insiders 0.0079 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 8.43
Target Low Price 10.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 7.17
Open 8.43 Free Cashflow -45628000 State MD
Dividend Yield 0.00 % Return On Assets -0.3956 Time Zone Short Name EST
Trailing Eps -1.57 Day Low 8.23 Address1 910 Clopper Road
Shares Outstanding 71 M Price Hint 2 Target High Price 28.00
Website https://altimmune.com 52 Week Change 1.76 Average Volume 2 M
Forward Eps -1.47 Recommendation Key buy Compensation As Of Epoch Date 1 B
Quick Ratio 1652.20 % Last Split Factor 1:30 Regular Market Day High 9.00
Is_sp_500 False Profit Margins 0.00 % Debt To Equity 1.33
Fifty Two Week High 14.84 Day High 9.00 Shares Short 22 M
Regular Market Open 8.43 Industry Key biotechnology Earnings Growth 0.00 %
Enterprise To Revenue 9294.44 Revenue Growth -98.60 % Shares Percent Shares Out 0.3211
Operating Cashflow -78116000 Currency USD Time Zone Full Name America/New_York
Market Cap 620 M Is_nasdaq_100 False Zip 20878
Quote Type EQUITY Industry Biotechnology Ex Dividend Date 1 B
Regular Market Day Low 8.23 Held Percent Institutions 0.5672 Long Name Altimmune, Inc.
Current Price 8.73 Address2 Suite 201S Enterprise To Ebitda -4.87
Financial Currency USD Current Ratio 16.87 Industry Disp Biotechnology
Number Of Analyst Opinions 8 Country United States Float Shares 70 M
Two Hundred Day Average 7.56 Ir Website http://ir.pharmathene.com/phoenix.zhtml?c=191999&p=irol-irhome Enterprise Value 483 M
Price To Sales Trailing12 Months 11940.73 Forward PE -7.81 Regular Market Volume 2 M
Ebitda -99191000 Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases.

The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.

It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus.

The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015.

Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.